Jeet Mukherjee
Stock Analyst at BTIG
(4.24)
# 1,411
Out of 5,182 analysts
45
Total ratings
63.64%
Success rate
13.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterates: Buy | $19 | $6.23 | +204.98% | 4 | Apr 23, 2026 | |
| AAPG Ascentage Pharma Group International | Reiterates: Buy | $48 | $22.34 | +114.86% | 3 | Apr 13, 2026 | |
| AARD Aardvark Therapeutics | Reiterates: Buy | $9 | $5.37 | +67.60% | 4 | Mar 24, 2026 | |
| ARVN Arvinas | Maintains: Buy | $14 → $16 | $10.42 | +53.55% | 3 | Mar 19, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $4.51 | +210.42% | 4 | Mar 17, 2026 | |
| IPHA Innate Pharma | Assumes: Buy | $8 | $1.37 | +483.94% | 1 | Mar 12, 2026 | |
| IBRX ImmunityBio | Assumes: Buy | $13 | $8.19 | +58.73% | 1 | Mar 12, 2026 | |
| AVBP ArriVent BioPharma | Assumes: Buy | $42 | $31.00 | +35.48% | 1 | Mar 12, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $138 → $134 | $87.17 | +53.72% | 6 | Feb 26, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $192 → $215 | $127.05 | +69.22% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $104 | $53.24 | +95.34% | 6 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $16.57 | +81.05% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $22.84 | +22.59% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.19 | +111.95% | 1 | Dec 18, 2025 |
Verastem
Apr 23, 2026
Reiterates: Buy
Price Target: $19
Current: $6.23
Upside: +204.98%
Ascentage Pharma Group International
Apr 13, 2026
Reiterates: Buy
Price Target: $48
Current: $22.34
Upside: +114.86%
Aardvark Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $9
Current: $5.37
Upside: +67.60%
Arvinas
Mar 19, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $10.42
Upside: +53.55%
Perspective Therapeutics
Mar 17, 2026
Reiterates: Buy
Price Target: $14
Current: $4.51
Upside: +210.42%
Innate Pharma
Mar 12, 2026
Assumes: Buy
Price Target: $8
Current: $1.37
Upside: +483.94%
ImmunityBio
Mar 12, 2026
Assumes: Buy
Price Target: $13
Current: $8.19
Upside: +58.73%
ArriVent BioPharma
Mar 12, 2026
Assumes: Buy
Price Target: $42
Current: $31.00
Upside: +35.48%
Kymera Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $138 → $134
Current: $87.17
Upside: +53.72%
Palvella Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $192 → $215
Current: $127.05
Upside: +69.22%
Feb 23, 2026
Reiterates: Buy
Price Target: $104
Current: $53.24
Upside: +95.34%
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $16.57
Upside: +81.05%
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $22.84
Upside: +22.59%
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $5.19
Upside: +111.95%